BRPI1005695A2 - derivados de álcool 1-fenil-2-piridinil alquila como inibidores de fosfodiesterase - Google Patents

derivados de álcool 1-fenil-2-piridinil alquila como inibidores de fosfodiesterase

Info

Publication number
BRPI1005695A2
BRPI1005695A2 BRPI1005695A BRPI1005695A BRPI1005695A2 BR PI1005695 A2 BRPI1005695 A2 BR PI1005695A2 BR PI1005695 A BRPI1005695 A BR PI1005695A BR PI1005695 A BRPI1005695 A BR PI1005695A BR PI1005695 A2 BRPI1005695 A2 BR PI1005695A2
Authority
BR
Brazil
Prior art keywords
phenyl
alkyl alcohol
alcohol derivatives
phosphodiesterase inhibitors
pyridinyl alkyl
Prior art date
Application number
BRPI1005695A
Other languages
English (en)
Inventor
Armani Elisabetta
Amari Gabriele
Delcanale Maurizio
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1005695(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BRPI1005695A2 publication Critical patent/BRPI1005695A2/pt
Publication of BRPI1005695A8 publication Critical patent/BRPI1005695A8/pt
Publication of BRPI1005695B1 publication Critical patent/BRPI1005695B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI1005695-5A 2009-02-06 2010-02-04 Compostos, processo para a preparação de um composto, combinação de um composto, composição farmacêutica, usos de um composto, dispositivo e kit BRPI1005695B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001660A EP2216327A1 (en) 2009-02-06 2009-02-06 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP09001660.1 2009-02-06
PCT/EP2010/000676 WO2010089107A1 (en) 2009-02-06 2010-02-04 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors

Publications (3)

Publication Number Publication Date
BRPI1005695A2 true BRPI1005695A2 (pt) 2017-06-06
BRPI1005695A8 BRPI1005695A8 (pt) 2017-12-26
BRPI1005695B1 BRPI1005695B1 (pt) 2026-02-24

Family

ID=

Also Published As

Publication number Publication date
RS52605B (sr) 2013-04-30
WO2010089107A1 (en) 2010-08-12
UA102574C2 (ru) 2013-07-25
AU2010211274A1 (en) 2011-08-25
MA33105B1 (fr) 2012-03-01
CY1113764T1 (el) 2016-07-27
CL2011001876A1 (es) 2011-10-28
PE20120055A1 (es) 2012-02-16
US20100204256A1 (en) 2010-08-12
JP5612610B2 (ja) 2014-10-22
CN102317262A (zh) 2012-01-11
SG173208A1 (en) 2011-09-29
NZ594413A (en) 2013-05-31
JP2015038079A (ja) 2015-02-26
JO2761B1 (en) 2014-03-15
TN2011000346A1 (en) 2013-03-27
US8440834B2 (en) 2013-05-14
CN102317262B (zh) 2014-08-06
US8648204B2 (en) 2014-02-11
ES2395528T3 (es) 2013-02-13
EP2393782A1 (en) 2011-12-14
BRPI1005695A8 (pt) 2017-12-26
GEP20135919B (en) 2013-09-10
TWI459945B (zh) 2014-11-11
PL2393782T3 (pl) 2013-02-28
US20140179647A1 (en) 2014-06-26
US9056176B2 (en) 2015-06-16
SI2393782T1 (sl) 2013-01-31
US20140378423A1 (en) 2014-12-25
IL214446A0 (en) 2011-09-27
MY152048A (en) 2014-08-15
EP2393782B1 (en) 2012-09-12
US20130012487A1 (en) 2013-01-10
TW201032804A (en) 2010-09-16
HK1162508A1 (en) 2012-08-31
US20130289010A1 (en) 2013-10-31
IL214446A (en) 2014-12-31
US8859778B2 (en) 2014-10-14
EA019113B1 (ru) 2014-01-30
ME02325B (me) 2016-06-20
MX2011007857A (es) 2011-08-15
CA2751494A1 (en) 2010-08-12
KR101337728B1 (ko) 2013-12-09
JP2012516863A (ja) 2012-07-26
AR075243A1 (es) 2011-03-16
AU2010211274B2 (en) 2016-03-17
CO6400217A2 (es) 2012-03-15
PT2393782E (pt) 2012-12-26
EP2216327A1 (en) 2010-08-11
HRP20121004T1 (hr) 2012-12-31
CA2751494C (en) 2017-03-07
KR20110094356A (ko) 2011-08-23
EA201190099A1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
BRPI0814065A2 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BR112012000792A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BRPI1009800A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
CO6831983A2 (es) Compuestos heterocíclicos como inhibidores de cinasas
SMT201400116B (it) Pirimidinoni come inibitori delle PI13K
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
CO6801747A2 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
BRPI1014708A2 (pt) dihidropirimidinonas para uso como inibidores de bace2
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
HRP20171534T8 (hr) Derivati fosfora kao inhibitori kinaza
PL2456444T3 (pl) Pochodne adeniny jako inhibitory PI3K
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
EP2473053A4 (en) SUBSTITUTED XANTHINE DERIVATIVES
BR112013015449A2 (pt) compostos de bi-heteroarila como inibidores de vps23
BRPI0912475A2 (pt) compostos como inibidores de quinase
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
ZA201309150B (en) Derivatives of 1-phenyl-2-pyridinyl- alkyl alcohols as phosphodiesterase inhibitors
BRPI0914759A2 (pt) derivado de alquil pirimidin-4-ona substituída
LT3070091T (lt) Benzodioksolo dariniai kaip fosfodiesterazės inhibitoriai
BRPI1015367A2 (pt) imidazotiodiazois para uso como inibidores de cinase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.